BRIEF-Alnylam presents updated results from phase 1/2 study of ALN-CC5 in patients with paroxysmal nocturnal hemoglobinuria

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.